for the Period Ended 30 November 2025
| Directors report | |
| Profit and loss | |
| Balance sheet | |
| Additional notes | |
| Balance sheet notes | |
| Community Interest Report |
Directors' report period ended
The directors present their report with the financial statements of the company for the period ended 30 November 2025
Principal activities of the company
Directors
The directors shown below have held office during the whole of the period from
1 December 2024
to
30 November 2025
The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006
This report was approved by the board of directors on
And signed on behalf of the board by:
Name:
Status: Director
for the Period Ended
| 2025 | 2024 | |
|---|---|---|
|
|
£ |
£ |
| Turnover: |
|
|
| Cost of sales: |
(
|
(
|
| Gross profit(or loss): |
|
( |
| Administrative expenses: |
(
|
(
|
| Other operating income: |
|
|
| Operating profit(or loss): |
|
( |
| Profit(or loss) before tax: |
|
( |
| Profit(or loss) for the financial year: |
|
( |
As at
| Notes | 2025 | 2024 | |
|---|---|---|---|
|
|
£ |
£ |
|
| Fixed assets | |||
| Tangible assets: | 3 |
|
|
| Total fixed assets: |
|
|
|
| Current assets | |||
| Debtors: | 4 |
|
|
| Cash at bank and in hand: |
|
|
|
| Total current assets: |
|
|
|
| Creditors: amounts falling due within one year: | 5 |
(
|
(
|
| Net current assets (liabilities): |
( |
( |
|
| Total assets less current liabilities: |
( |
( |
|
| Total net assets (liabilities): |
( |
( |
|
| Members' funds | |||
| Profit and loss account: |
( |
( |
|
| Total members' funds: |
( |
( |
The notes form part of these financial statements
This report was approved by the board of directors on
and signed on behalf of the board by:
Name:
Status: Director
The notes form part of these financial statements
for the Period Ended 30 November 2025
Basis of measurement and preparation
Turnover policy
Tangible fixed assets depreciation policy
Other accounting policies
for the Period Ended 30 November 2025
| 2025 | 2024 | |
|---|---|---|
| Average number of employees during the period |
|
|
for the Period Ended 30 November 2025
| Land & buildings | Plant & machinery | Fixtures & fittings | Office equipment | Motor vehicles | Total | |
|---|---|---|---|---|---|---|
| Cost | £ | £ | £ | £ | £ | £ |
| At 1 December 2024 |
|
|
||||
| Additions | ||||||
| Disposals | ||||||
| Revaluations | ||||||
| Transfers | ||||||
| At 30 November 2025 |
|
|
||||
| Depreciation | ||||||
| At 1 December 2024 |
|
|
||||
| Charge for year |
|
|
||||
| On disposals | ||||||
| Other adjustments | ||||||
| At 30 November 2025 |
|
|
||||
| Net book value | ||||||
| At 30 November 2025 |
|
|
||||
| At 30 November 2024 |
|
|
for the Period Ended 30 November 2025
| 2025 | 2024 | |
|---|---|---|
| £ | £ | |
| Prepayments and accrued income |
|
|
| Other debtors |
|
|
| Total |
|
|
for the Period Ended 30 November 2025
| 2025 | 2024 | |
|---|---|---|
| £ | £ | |
| Trade creditors |
|
|
| Accruals and deferred income |
|
|
| Other creditors |
|
|
| Total |
|
|
During the 2024–2025 financial year, TONIBOBANDLOU CIC delivered a programme of work focused on improving the experience of women navigating mastectomy and breast reconstruction. The company produced, printed and introduced BRAVE v1.0, the UK’s first magazine style visual decision aid for mastectomy, designed and shaped with women of lived experience. BRAVE was adopted within Oxford University Hospitals, where Clinical Nurse Specialists and Consultants used it in pre-operative conversations to strengthen informed consent and reduce patient anxiety. As one clinician noted, “many finding the images reassuring and giving a better idea of what to expect.” The company completed a full qualitative evaluation involving 21 women, generating 916 analysable comments. Women described BRAVE as “calming, validating and empowering,” highlighting its role in improving understanding and confidence at a critical point in their cancer pathway. TONIBOBANDLOU CIC also expanded its representative image library through ongoing photography with women across multiple surgical stages, ensuring that BRAVE reflects real bodies and real timelines. More than 200 hours were invested in direct community engagement, including interviews, photography sessions, return visits and individual image presentations. This relational approach ensured that BRAVE was shaped with women, not simply informed by them. Beyond direct patient impact, the company contributed to national sector learning. BRAVE was shared with over 150 professionals through webinars, NHS England meetings, Cancer Alliance discussions and national events. The organisation strengthened partnerships with Against Breast Cancer, Thames Valley Cancer Alliance and other charities, supporting recruitment, visibility and alignment with NHS priorities. The company also held a community fundraising event, presented BRAVE publicly for the first time, and continued to build a supportive network of women, clinicians and advocates. Together, these activities delivered clear community benefit by improving access to realistic imagery, contextualised information and emotionally intelligent decision support for women facing complex surgical decisions.
TONIBOBANDLOU CIC engages a wide range of stakeholders who are directly affected by, or contribute to, the development and use of BRAVE. These include women with lived experience of mastectomy and breast reconstruction, Clinical Nurse Specialists, Consultants, surgical advisors, national breast cancer charities, Cancer Alliances, researchers, and wider professional networks across the UK. Women of lived experience: Women were central to all decision-making and design processes. Across the year, the company invested over 200 hours in interviews, photography sessions, return visits, image review conversations and individual presentations of their photographs. Women provided detailed feedback through a full qualitative evaluation (21 participants, 916 analysable comments). Their reflections shaped the emotional tone, clarity of information, diversity of imagery and accessibility of BRAVE v1.0. Women described BRAVE as “calming, validating and empowering,” and their feedback directly informed refinements for BRAVE v1.1 and future versions. Clinical stakeholders: Clinical Nurse Specialists and Consultants at Oxford University Hospitals used BRAVE v1.0 in pre-operative conversations and provided ongoing feedback on its clinical utility. As one Specialist Nurse noted, “many finding the images reassuring and giving a better idea of what to expect.” Their insights guided improvements to sequencing, clarity of surgical explanations and the integration of BRAVE into informed consent discussions. BRAVE was also used within NHS training by Assistant Professor Dr Gemma McKenna, whose feedback strengthened the resource’s alignment with shared decision making principles. Charities and sector organisations: Stakeholders such as Against Breast Cancer, Thames Valley Cancer Alliance, Breast Cancer Now and Future Dreams House provided feedback on recruitment, sector needs and patient information gaps. Their input supported alignment with NHS priorities, strengthened visibility, and informed strategic planning for wider adoption. Professional networks and national engagement: Over 150 professionals engaged with BRAVE through webinars, NHS England meetings, sector events and national conferences. Feedback emphasised the importance of realistic imagery, lived experience insight and emotionally intelligent information. This consultation reinforced BRAVE’s relevance and guided the development of future versions and partnership pathways. Community stakeholders: A community fundraising event provided an opportunity for supporters and partners to engage with BRAVE directly. Feedback from this event informed how the resource is presented publicly and helped shape communication materials for wider audiences. Actions taken in response to stakeholder feedback: Stakeholder consultation directly influenced the refinement of BRAVE v1.0, the design of BRAVE v1.1, the expansion of the image library, improvements to clinical clarity, and the strategic direction for NHS Cancer Alliance adoption. Feedback also shaped the emotional tone, accessibility and representativeness of the resource, ensuring it remains grounded in lived experience and clinical need.
The Co-Founders of the CIC, bill monthly a symbolic remuneration of £0.17. This figure represents the 1 in 7 women who are diagnosed with Breast Cancer in the UK every year.
No transfer of assets other than for full consideration
This report was approved by the board of directors on
8 July 2026
And signed on behalf of the board by:
Name: Louise Mckenna-Mayes
Status: Director